ReviewCureus2025
Neuroinvasive Potential of Monkeypox Virus: A 25-Year Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neurological manifestations of Mpox virus during the recent global outbreak: a systematic review.BMC infectious diseases · 2025Pooled it
- One-Pot RPA-CRISPR/Cas12a Assay With Visual Readout for the Ultra-Specific Detection of Monkeypox Virus Clade I.Microbial biotechnology · 2026Article
- Clinical Characteristics and Outcome of MPOX Patients Admitted to the Bukavu University Clinics in the Democratic Republic of Congo From July to December 2024: Open Cohort Study.Journal of tropical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox (MPX) is a zoonotic disease, caused by the MPX virus. Clinical symptoms and signs of the disease are similar to, but less severe than, smallpox, presenting with fever, headache, lymphadenopathy, back pain, myalgia, and skin rash. MPX can affect the central nervous system causing different complications, including encephalitis, cerebral edema, and intracranial hemorrhage. This study aimed to assess the neurological sequelae of MPX infection focusing on the available literature. An extensive data search was conducted in September 2024, covering the period from January 2000 to August 2024, using PubMed Central and Google Scholar. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) strategy was employed along with a combination of keywords to enlist all articles with data on MPX and its neurological manifestations, diagnosis, and treatment. All open-access case reports, case series, and original research articles in the English language, providing data on confirmed cases of MPX virus infection with documented neurological manifestations involving the brain, were reviewed. A total of 25 studies containing data on 758 patients were included in this systematic review. The mean age and standard deviation of included patients was 26.77±12.17 years, with a female predominance (65.27%). Most of the cases (87.05%) were transmitted by animal/human contact. Fatigue/malaise (34.37%) was the most common presentation, followed by fever and headache accounting for 31.27% and 29.84%, respectively. Limb weakness/numbness (20.83%) was the most common examination finding. About 26.32% had normal glucose levels and 21.05% reported raised white blood cells on CSF routine examination. T2 hyperintensities and fluid-attenuated inversion recovery (FLAIR) hyperintensities were reported on magnetic resonance imaging in 18.75% of the cases, each. Brainstem involvement, cortical, and thalamic involvement were seen in 18.60%, 16.28%, and 13.95% of cases, respectively. About 34.61% of the patients were inadvertently given antibiotics. The emerging MPX neurological involvement is alarming and requires a prompt response. The neurotropism of MPXV is still in debate and needs to be explored. Early identification and interventions by healthcare providers can significantly impact the trajectory of MPX spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.